title: Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers.
abstract: The knowledge that our immune system can be exploited for control or even eradication of acute myeloid leukemia (AML) has sparked a strong interest in therapeutic vaccine strategies to mount effective anti-leukemic immunity in AML patients. One of the most tantalizing approaches in this regard involves the use of dendritic cell-based vaccines. Dendritic cells (DCs) are antigen-presenting cells, capable of inducing anti-leukemic immune responses directed against leukemia-associated antigens. They can be obtained in high numbers following in vitro differentiation of peripheral blood monocytes. Research efforts are now focused on optimizing in vitro culture conditions and antigen loading strategies of DCs in order to maximize their potential to induce anti-leukemic immunity. Here, we will highlight some important aspects in the design of a potent DC vaccine for AML. We also discuss the importance of natural killer cells and combination strategies to further improve the outcome of DC-based vaccination in AML patients.
authors.affiliation: University of Antwerp, Vaccine & Infectious Disease Institute-Laboratory of Experimental Hematology, Wilrijk (Antwerp), Belgium.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Anguille
authors.forename: Eva
authors.initials: E
authors.lastname: Lion
authors.forename: Evelien
authors.initials: E
authors.lastname: Smits
authors.forename: Zwi N
authors.initials: ZN
authors.lastname: Berneman
authors.forename: Viggo F I
authors.initials: VF
authors.lastname: van Tendeloo
mesh_terms: D001709:Biotechnology / Q000379:methods; D018929:Cell Culture Techniques; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D016896:Treatment Outcome